ClinicalTrials.gg

Program

nelitolimod

Also written as “SD-101”, “SD-101 Dermal Cream (6%)” and “SD-101-6.0 cream”.

Its studies are mostly in Epidermolysis Bullosa · Carcinoma, Hepatocellular · Uveal Melanoma · Melanoma · Lymphoma, B-Cell, led by 5 companies.

Furthest: phase 3, since Feb 13, 201514 company-led studies, 3 open or runningNext primary completion: May 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceutical40 open or runningphase 3since Feb 13, 2015Dec 12, 2013none ahead
Sanofi40 open or runningphase 2since Oct 13, 2014Jan 11, 2008none ahead
TriSalus Life Sciences31 open or runningphase 2since Jan 21, 2022Jun 2, 2021Sep 2027phase 1 · NCT05607953
Paradigm Therapeutics22 open or runningphase 3since Mar 4, 2026Mar 4, 2026May 17, 2027phase 3 · NCT07482787
Merck10 open or runningphase 1since Apr 4, 2016Apr 4, 2016none ahead

Also a collaborator on its studies: synteract-inc and ppd-development-lp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2008First study: phase 1 study in HealthyNew to SanofiSanofi · NCT00599001 · 26 enrolled · United States
  2. Jan 14, 2009Phase 1 study in Hepatitis C, ChronicSanofi · NCT00823862 · 34 enrolled · Poland
  3. Dec 12, 2013BioMarin Pharmaceutical's first study: phase 2 study in Epidermolysis BullosaNew to BioMarin PharmaceuticalBioMarin Pharmaceutical · NCT02014376 · 48 enrolled · United States
  4. Mar 12, 2014Phase 2 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02090283 · 42 enrolled · United States
  5. Oct 13, 2014Phase 2 study in Lymphoma, B-CellSanofi · NCT02266147 · 29 enrolled · United States
  6. Feb 13, 2015Phase 3 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02384460 · 169 enrolled · United States, Australia, Austria and more
  7. Jul 28, 2015Phase 3 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02670330 · 152 enrolled · United States, Australia, Austria and more
  8. Jul 30, 2015Phase 2 study in MelanomaSanofi · NCT02521870 · 241 enrolled · United States, Australia, Germany and more
  9. Apr 4, 2016Merck's first study: phase 1 study in NeoplasmsNew to MerckMerck · NCT02731742 · 14 enrolled
  10. Jun 2, 2021TriSalus Life Sciences's first study: phase 1 study in Uveal MelanomaNew to TriSalus Life SciencesTriSalus Life Sciences · NCT04935229 · 67 enrolled · United States
  11. Jan 21, 2022Phase 2 study in Carcinoma, HepatocellularTriSalus Life Sciences · NCT05220722 · 23 enrolled · United States
  12. Oct 19, 2022Phase 1 study in Locally Advanced Pancreatic AdenocarcinomaTriSalus Life Sciences · NCT05607953 · 60 enrolled · United States
  13. Mar 4, 2026Paradigm Therapeutics's first studies: 2 phase 3 studies in Epidermolysis BullosaNew to Paradigm TherapeuticsParadigm Therapeutics · NCT07482813, NCT07482787

Ahead

  1. May 17, 2027Primary completion: phase 3 study in Epidermolysis BullosaParadigm Therapeutics · NCT07482787
  2. Sep 2027Primary completion: phase 1 study in Locally Advanced Pancreatic AdenocarcinomaTriSalus Life Sciences · NCT05607953
  3. Sep 19, 2027Primary completion: phase 3 study in Epidermolysis BullosaParadigm Therapeutics · NCT07482813

TargetBeta

TLR9 →read by rule
“A class C CpG-oligodeoxynucleotide (ODN) agonist of toll-like receptor 9 (TLR9), with immunostimulatory, immunoadjuvant and antineoplastic activities”NCIt, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07482813Epidermolysis Bullosa3Not yet recruitingParadigm TherapeuticsSep 19, 202780
NCT07482787Epidermolysis Bullosa · United States3RecruitingParadigm TherapeuticsMay 17, 202780
NCT05607953Locally Advanced Pancreatic Adenocarcinoma · United States1Active, not recruitingTriSalus Life SciencesSep 202760
NCT05220722Carcinoma, Hepatocellular · United States2TerminatedTriSalus Life SciencesJul 31, 202423
NCT04935229Uveal Melanoma · United States1TerminatedTriSalus Life SciencesJul 17, 202467
NCT02731742Neoplasms1TerminatedMerckJan 8, 201814
NCT02521870Melanoma · United States, Australia, Germany and more2TerminatedSanofiApr 2020241
NCT02670330Epidermolysis Bullosa · United States, Australia, Austria and more3TerminatedBioMarin PharmaceuticalSep 3, 2018152
NCT02384460Epidermolysis Bullosa · United States, Australia, Austria and more3CompletedBioMarin PharmaceuticalJul 5, 2017169
NCT02266147Lymphoma, B-Cell · United States2TerminatedSanofiApr 201729
NCT02090283Epidermolysis Bullosa · United States2TerminatedBioMarin PharmaceuticalSep 14, 201842
NCT02014376Epidermolysis Bullosa · United States2CompletedBioMarin PharmaceuticalJun 24, 201448
NCT00823862Hepatitis C, Chronic · Poland1CompletedSanofiDec 200934
NCT00599001Healthy · United States1CompletedSanofiMar 200826

How it is read

Names in the registry

  • “SD-101”, 7 entries
  • “SD-101 Dermal Cream (6%)”, 3 entries
  • “SD-101-6.0 cream”, 2 entries
  • “SD-101(1)”, 1 entry
  • “SD-101(2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.